Pharmafile Logo
Pharmafocus logo
Advanced Search

liraglutide

Showing 11 posts of 11 posts found.

nice_new_london_office_internal_3_web

NICE recommends Novo’s liraglutide for management of obesity and non-diabetic hyperglycaemia

October 30, 2020
Medical Communications, Sales and Marketing NICE, Novo Nordisk, liraglutide

Novo Nordisk’s pre-filled injection Saxenda (liraglutide) has received the backing of drug watchdog NICE, meaning it will now be made …

News
novo_flag

FDA approves Novo Nordisk’s Victoza for children with type 2 diabetes

June 18, 2019
Manufacturing and Production GLP-1, Novo Nordisk, Victoza, diabetes, liraglutide

The FDA has approved Novo Nordisk’s Victoza (liraglutide) for paediatric patients aged 10 years and older with type 2 diabetes. …

News

Weight loss drug reduces diabetes risk by 80%, according to ICL research

February 27, 2017
Research and Development, Sales and Marketing diabetes, icl, liraglutide

Researchers from Imperial College London have published research showing that use of weight loss drug liraglutide lowered the risk of …

News
novo_flag

Novo Nordisk presents positive long-term results for Saxenda

June 3, 2016
Medical Communications, Research and Development Novo Nordisk, cardiometabolic risk factors, liraglutide, saxenda, weight loss

Novo Nordisk has presented analysis covering three years of a late-stage trial for Saxenda (liarglutide 3mg) , which showed the …

News

Jardiance scores more cardiovascular outcomes data

November 10, 2015
Manufacturing and Production Boehringer, Boehringer Ingelheim, Eli Lilly, Novo Nordisk, Victoza, cardiovascular outcomes, diabetes, empagliflozin, jardiance, lilly, liraglutide, type 2 diabetes

A sub-group analysis of data from an outcomes study of Boehringer Ingelheim’s and Lilly’s Jardiance has found the diabetes drug …

News
Novo image

Novo Nordisk obesity drug is launched in the US

April 23, 2015
Sales and Marketing Novo Nordisk, liraglutide, obesity, overweight, saxenda, world health organization

Novo Nordisk is rolling out its obesity drug Saxenda across the US for the treatment of obese adult patients. Saxanda …

News
Saxenda image

Novo Nordisk obesity drug gets EU approval

March 24, 2015
Sales and Marketing EMA, EU, FDA, Victoza, liraglutide, obesity, saxenda

Novo Nordisk’s obesity drug Saxenda has been approved by the European Commission for use across the EU. This approval follows …

News
Saxenda image

Novo Nordisk obesity drug shows added benefits

March 9, 2015
Sales and Marketing (liraglutide), Contrave, Novo Nordisk, Victoza, Xenical, liraglutide, obesity, saxenda, weight

New research by Novo Nordisk has suggested that its obesity drug Saxenda can help improve several other weight-related problems as …

News
Novo image

Novo Nordisk obesity drug gets FDA nod

December 24, 2014
Sales and Marketing FDA, Novo Nordisk, Victoza, diabetes, liraglutide, saxenda

The US Food and Drug Administration has shown Novo Nordisk’s obesity drug Saxenda the green light to aid chronic weight …

News
Novo Nordisk's type II diabetes drug Victoza (liraglutide)

Novo’s diabetes drug Victoza approved in China

March 16, 2011
Sales and Marketing Glucagon-Like Peptide-1, Novo Nordisk, Victoza, diabetes in China, liraglutide, type 2 diabetes

Novo Nordisk’s injectable diabetes drug Victoza has been given regulatory approval in China. The Chinese State Food and Drug Administration …

News
Novo Nordisk's Victoza

Diabetes drugs show promise in Alzheimer’s

January 17, 2011
Research and Development Alzheimer's, Alzheimer’s, Byetta, Novo Nordisk, Victoza, diabetes, exenatide, lilly, liraglutide

Research suggests that new diabetes drugs enhance cell growth in the brain, and could help treat Alzheimer’s disease. Researchers at …

News

Latest content

IDEAYA Biosciences announces first-patient-in for phase 1 clinical trial evaluating IDE397 and Trodelvy combination in MTAP-deletion bladder cancer

June 27, 2024

Immunotherapy created at Roswell Park Comprehensive Cancer Center given expanded ODD by FDA

June 27, 2024

Abcuro completes enrolment for phase 2/3 IBM treatment trial

June 26, 2024

AskBio initiates phase 2 Parkinson’s trial recruitment

June 26, 2024

AstraZeneca’s Tagrisso approved in Japan for lung cancer treatment

June 25, 2024